pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

11 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT800Endpoints604BioPharma Dive231onclive165Fierce Biotech74BioSpace70raps29
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology
  • Sanofi MS drug rejected in US gets an endorsement in Europe
    Tolebrutinib, which the FDA recently turned back due to safety concerns, received a positive recommendation that positions the therapy for its first regulatory approval.
    BioPharma Dive · 3mo ago↗ source
  • Novartis pulls Pluvicto prostate cancer label expansion filing in the EU
    Novartis has withdrawn its EU application for Pluvicto's expansion into earlier prostate cancer treatment, despite US and UK approval for the same indication. The Swiss drugmaker failed to gain fav…
    Endpoints · 3mo ago↗ source
  • Lilly tumbles on Foundayo’s shaky week; FDA to issue vouchers for psychedelics
    Lilly shares dipped, and Novo’s climbed, as Foundayo’s early trajectory diverged from that of oral Wegovy. Elsewhere, Regeneron inked a drug price deal and two companies announced leadership changes.
6
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
BioPharma Dive · 3mo ago
↗ source
  • Drugmaker AbbVie chooses North Carolina for $1.4B manufacturing campus
    The 185-acre site will be the company’s largest single investment to date, with a focus on small-volume parenteral products like vials and prefilled syringes.
    BioPharma Dive · 3mo ago↗ source
  • Roche, facing biosimilar threats, puts faith in new cancer and obesity drugs
    On a conference call, executives claimed that a closely watched breast cancer pill and portfolio of weight loss medicines could bank more than $9 billion annually.
    BioPharma Dive · 3mo ago↗ source
  • Sanofi posts upbeat sales as R&D pressure builds
    A string of research setbacks have left the pharmaceutical giant at a crossroads just as a new CEO is set to take over. But positive first-quarter earnings provided the company with a needed boost.
    BioPharma Dive · 3mo ago↗ source
  • Roche says its investigational breast cancer pill could outsell Herceptin
    Roche still has high sales hopes for its breast cancer pill giredestrant despite the drug’s failure in a first-line trial earlier this year. CEO Thomas Schinecker said Thursday that the drug could ...
    Endpoints · 3mo ago↗ source
  • BridgeBio’s oncology spinoff swaps out CEOs as it seeks to accelerate KRAS work
    BridgeBio Oncology Therapeutics is replacing CEO Eli Wallace, putting its CSO Pedro Beltran in the role, and making board member Neil Kumar executive chairman. The changes come as there’s been grow…
    Endpoints · 3mo ago↗ source
  • Revolution drug shows promise in early pancreatic cancer
    The findings build on data suggesting Revolution’s therapy could upend treatment for a notoriously tough-to-treat tumor and generate billions in sales.
    BioPharma Dive · 3mo ago↗ source
  • Merck adds to pharma’s AI push; Roche details MS drug results
    Merck is making a $1 billion investment in a deal with Google Cloud. Elsewhere, Roche pitched its case for a closely watched multiple sclerosis pill and Arcus and Gilead are ending a yearslong alli…
    BioPharma Dive · 3mo ago↗ source
  • An ‘AI scientist’ can tackle drug R&D. What does that mean for pharma?
    A new tool is giving researchers a “data center full of genius Ph.D. students in their pocket.”
    BioPharma Dive · 3mo ago↗ source